Join
Live feed
·
PRReleasevia Quantisnow
Sol-Gel Technologies Ltd. logo

Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome

ByQuantisnow·Wall Street's wire, on your screen.
SLGL· Sol-Gel Technologies Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SLGL (Sol-Gel Technologies Ltd.) and more on Quantisnow.